Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

Jean Abou Yared, MD, Theodore Girinsky, MD, Serge Koscielny, PhD, Vincent Ribrag, MD, Patrice Carde, MD, Suzanna Ceapa, MD, Christophe Ferme, MD

Blood (2008) 112 (11): 1768.

https://doi.org/10.1182/blood.V112.11.1768.1768

Published: 2008

Journal Articles

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

Valerie Camara-Clayette, PhD, Serge Koscielny, PhD, Thierry Lamy, MD, PhD, Thierry Fest, MD, Marc Bernard, MD, Vincent Ribrag, MD

Blood (2006) 108 (11): 2589.

https://doi.org/10.1182/blood.V108.11.2589.2589

Published: 2006

Journal Articles

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Valerie Camara-Clayette, PhD, William Vainchenker, MD, phD, Serge Koscielny, phD, Olivier Hermine, MD, phD, Vincent Ribrag, MD

Blood (2006) 108 (11): 4602.

https://doi.org/10.1182/blood.V108.11.4602.4602

Published: 2006

Journal Articles

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Vincent Ribrag, MD, Serge Koscielny, phD, Olivier Casasnovas, MD, Cecile Cazeneuve, MD, phD, Pauline Brice, MD, Franck Morschhauser, MD, Jean Gabarre, MD, Marine Divine, MD, Laurent Voillat, MD, Apasia Stamatoullas, MD, Gilbert Lenoir, phD, Gilles Andre Salles, MD, phD

Blood (2006) 108 (11): 2266.

https://doi.org/10.1182/blood.V108.11.2266.2266

Published: 2006

Journal Articles

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Jean-Henri Bourhis, MD, Yasmina Bouko, MD, Serge Koscielny, PhD, Hildegard Greinix, MD, Gunter Derigs, MD, Gilles Salles, MD, Walter Feremans, MD, Marleen Bakkus, PhD, Jane Apperley, MD, Diana Samson, MD, Bo Bjorkstrand, MD, Dietger Niederwieser, MD, Gosta Gahrton, MD, Jose-Luis Pico, MD, Hartmut Goldschmidt, MD

Blood (2004) 104 (11): 921.

https://doi.org/10.1182/blood.V104.11.921.921

Published: 2004

NARROW

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.

Implication of BMP7 in Human Mantle Cell Lymphoma (MCL) Secondary Drug Resistance.

JNK Pathway Is Constitutively Activated and Is Required for Survival in Human Mantle-Cell Lymphoma Fresh Cells and Cell-Lines.

Pharmacogenetic Study in Hodgkin’s Lymphomas, Impact of UGT1A1 on Prognosis.

Long Term Follow-Up Shows No Clinical Benefit for CD34 + Selection of Autologous Transplants Following Myeloablative Therapy in Patients with Newly Diagnosed Myeloma : An EBMT Phase III Randomized Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only